Hepatitis B
B-United
EU CT Nummer:
Recruitment starts January 2025
A Phase 2b, multi-centre, randomised, partially placebo controlled, observer-blind study to investigate the safety andefficacy of sequential therapy with Daplusiran/Tomligisiranfollowed by bepirovirsen in participants with chronic hepatitis B virus on background nucleos(t)ide analogue therapy (B-United)
Objective
Functional healing, weaning of NA-therapy (HBsAG loss)
We are looking for patients with:
- HepB with current NA-therapy
No HIV/ HCV/ HDV co-infections
HBsAG > 100 IU/mL
HBV DNA < 90 IU/mL
If you are interested in the study, please speak to your family doctor or infectiologist. You can also contact us directly by email or via the contact form for more information.